• Post-combination company, SL Science Holding Limited, to commence trading on the Nasdaq Stock Market under the ticker symbol "SLBT"
  • Transaction provides strategic capital to advance proprietary Gamma delta T cell-based "off-the-shelf" cellular therapies for solid tumor indications, including pancreatic and brain cancers
  • Leadership team bolstered by seasoned executives and highly experienced independent directors to drive the next phase of clinical and commercial growth

     

TAIPEI, Taiwan, June 12, 2026 (GLOBE NEWSWIRE) -- SL BIO Ltd. ("SL Bio" or the "Company"), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and gene therapies, today announced the closing of its previously announced business combination with Horizon Space Acquisition II Corp. (NASDAQ:HSPT) ("Horizon Space"), a publicly traded special purpose acquisition company.

The business combination was approved by Horizon Space shareholders at an extraordinary general meeting on February 12, 2026. Upon closing of the business combination, SL Bio and Horizon Space became wholly owned subsidiaries of SL Science Holding Limited, a Cayman Islands holding company ("SL Science"). The ordinary shares of SL Science are expected to commence trading on the Nasdaq Global Market under the new ticker symbol "SLBT" beginning on June 15, 2026.